Regulatory Approval Update
Alembic Pharma Receives USFDA Final Approval for Dapagliflozin Tablets
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals has received USFDA final approval for Dapagliflozin tablets (5 mg and 10 mg), gaining access to a ~$10.5 billion market with 180 days of shared generic exclusivity.
PRICE-SENSITIVE TRIGGER
Event: USFDA final approval for generic drug
Type: Regulatory Approval Update
Impact: Positive
Immediate Effect: Opens significant revenue opportunity in US market
Key Metrics
- Market Size: ~$10.48 billion (IQVIA estimate)
- Exclusivity: 180 days shared generic exclusivity
Highlights
Market Opportunity: ~$10.5 billion
What Happened ?
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dapagliflozin Tablets (5 mg and 10 mg).
The approved drug is therapeutically equivalent to Farxiga (AstraZeneca) and is used for the treatment of type 2 diabetes and related cardiovascular conditions.
Key details
Product Details
- Dapagliflozin Tablets (5 mg & 10 mg)
- SGLT2 inhibitor used for diabetes and heart failure risk reduction
- Equivalent to reference drug Farxiga
Strategic Advantage
- Eligible for 180 days shared generic exclusivity
- Among early ANDA applicants with Para IV certification
Market Opportunity
- Estimated US market size: ~$10.48 billion
- Strong demand in diabetes and cardiovascular treatment segment
Company Strength
- Total USFDA approvals: 235 ANDAs
- Strong pipeline in US generics market
Risk Analysis
Key Risks
- Pricing pressure in US generics market
- Competition from other generic players
- Margin compression due to exclusivity sharing
Worst Case Scenario
High competition reduces pricing power and limits profit upside
Risk Level: Medium
Company Commentary
- Early mover advantage in Dapagliflozin segment
- Strong regulatory track record with USFDA
- Continued focus on expanding US generics portfolio
Official Exchange Filing: Alembic Pharmaceuticals Limited